Literature DB >> 28553928

Synergistic effects of deleting multiple nonessential elements in nonreplicative HSV-1 BAC genomic vectors play a critical role in their viability.

M Ventosa1, A Ortiz-Temprano1, H Khalique1, F Lim1.   

Abstract

Nonreplicative Herpes simplex virus type-1 (HSV-1) genomic vectors have already entered into clinical trials for neurological gene therapy thanks to their scalable growth in permissive cells. However, the small transgene capacity of this type of HSV-1 vectors currently used in the clinic represents an important limiting factor as a gene delivery system. To develop high-capacity nonreplicative genomic HSV-1 vectors, in this study we have characterized a series of multiply deleted mutants which we have constructed in bacterial artificial chromosomes (BACs), removing up to 24 kb of unstable or dispensable genomic sequences to allow insertion of transgenes up to this size. We show that synergistic effects of deletions of: the HSV-1 replication origins oriS and oriL, the HSV-1 internal repeat region, the remaining ICP4 gene copy and the genes encoding for ICP27, UL56, UL55, can severely reduce the growth of these HSV-1 vectors. Given that several of these elements have been characterized as 'non-essential' for viral growth in cell culture by single-deletion experiments of wild-type HSV-1, our study highlights the need to re-evaluate their functional contribution in the context of multiply deleted nonreplicative HSV-1 genomic vectors. Our BAC mutants described here can serve as useful starting platforms to accelerate HSV-1 vector development.

Entities:  

Mesh:

Year:  2017        PMID: 28553928     DOI: 10.1038/gt.2017.43

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  40 in total

Review 1.  Gene therapy clinical trials worldwide to 2012 - an update.

Authors:  Samantha L Ginn; Ian E Alexander; Michael L Edelstein; Mohammad R Abedi; Jo Wixon
Journal:  J Gene Med       Date:  2013-02       Impact factor: 4.565

2.  Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.

Authors:  Y Saeki; C Fraefel; T Ichikawa; X O Breakefield; E A Chiocca
Journal:  Mol Ther       Date:  2001-04       Impact factor: 11.454

3.  A cosmid-based system for constructing mutants of herpes simplex virus type 1.

Authors:  C Cunningham; A J Davison
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

4.  A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth.

Authors:  L E Post; B Roizman
Journal:  Cell       Date:  1981-07       Impact factor: 41.582

5.  Isolation of restriction endonuclease site deletion mutants of herpes simplex virus.

Authors:  S M Brown; J Harland; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1984-06       Impact factor: 3.891

6.  Activities of herpes simplex virus type 1 (HSV-1) ICP4 genes specifying nonsense peptides.

Authors:  N A DeLuca; P A Schaffer
Journal:  Nucleic Acids Res       Date:  1987-06-11       Impact factor: 16.971

7.  Deletion of the Herpes simplex 1 internal repeat sequences affects pathogenicity in the mouse.

Authors:  F J Jenkins; A M Donoghue; J R Martin
Journal:  Front Biosci       Date:  1996-10-04

8.  Gene therapy for pain: results of a phase I clinical trial.

Authors:  David J Fink; James Wechuck; Marina Mata; Joseph C Glorioso; James Goss; David Krisky; Darren Wolfe
Journal:  Ann Neurol       Date:  2011-07-27       Impact factor: 10.422

9.  A new logic for DNA engineering using recombination in Escherichia coli.

Authors:  Y Zhang; F Buchholz; J P Muyrers; A F Stewart
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

10.  A new positive/negative selection scheme for precise BAC recombineering.

Authors:  Shuwen Wang; Yuanjun Zhao; Melanie Leiby; Jiyue Zhu
Journal:  Mol Biotechnol       Date:  2009-01-22       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.